2.3 Special Donations

2.3 Special Donations

Quick Answer: Autologous units are collected for the same person who donated them (hemoglobin ≥11.0 g/dL or hematocrit ≥33%) and, in most U.S. practice, unused bags are discarded, not crossed over. Directed units are collected for a named recipient, require full allogeneic eligibility and testing, and are not inherently safer. Therapeutic phlebotomy treats hereditary hemochromatosis, polycythemia vera, or porphyria cutanea tarda; those units become allogeneic inventory only if the donor independently qualifies and FDA variance conditions (including no-charge phlebotomy for that condition) are met. Know the ISBT-128 labeling differences and the walking-donor / emergency-uncrossmatched distinctions so you do not promote a historical military practice or an issue-desk product into a “safer donor” story.

Special donations are still donations. 21 CFR 630.10 still requires a same-day eligibility decision before collection, informed acknowledgement, and a unique DIN. What changes is the intended recipient, the hemoglobin floor, the label, and whether an unused bag can ever become someone else’s transfusion.

Autologous donation

Preoperative autologous donation (PAD) is the classic BB autologous product: a patient donates one or more units in the weeks before scheduled surgery for later return to that same patient. Acute normovolemic hemodilution and intraoperative or postoperative salvage are related autologous strategies performed in the operating room rather than at a donor center; they are worth recognizing but they are not DHQ-driven community collections.

Because the donor and the recipient are the same person, some allogeneic bars are relaxed. The published hemoglobin/hematocrit floor is 11.0 g/dL or 33%, not the allogeneic 12.5/13.0 table. Donation intervals may be shortened under physician oversight so that several units can be collected before a surgery date (iron supplementation is often prescribed). Infectious-disease testing is still performed. A repeatedly reactive autologous unit is not quietly filed as “safe because it is the patient’s own blood.” If the patient’s physician and the blood-establishment physician still want that unit available, it is labeled with the required biohazard / reactive-test statements and issued only to that autologous recipient under documented exception — it is not crossed into allogeneic inventory.

Crossover means relabeling an unused autologous unit as allogeneic and putting it on the general shelf. Most current U.S. blood centers do not crossover. Autologous donors, as a group, have higher infectious-disease marker rates than volunteer allogeneic donors, and the process-control cost of proving that every autologous-specific exception has been reversed is not worth the rare extra unit. Unused autologous units are held for the patient through their outdate and then discarded. Exam options that say “after negative viral tests the unused autologous unit is released to any ABO-compatible recipient” describe a practice U.S. centers have largely abandoned, not current AABB/FDA-aligned operations.

Autologous units are labeled FOR AUTOLOGOUS USE ONLY under ISBT-128, with the patient’s identifiers as the intended recipient. They still require ABO/Rh confirmation before issue. They are not a reason to skip the clerical check.

Directed donation is not safer

A directed (sometimes called designated when a physician names a specific donor for a specific patient) unit is collected from a donor the patient or family chose. Typical motives are fear of the volunteer supply, a rare phenotype, or a wish to “keep it in the family.” The safety data do not support the fear: directed donors are more often first-time donors, and first-time donors have higher infectious-disease marker rates than repeat volunteer donors. Social pressure (“please don’t tell them I lived with someone who has HIV”) works against honest DHQ answers. Directed donation is not inherently safer. That sentence is an exam staple.

Directed donors must meet the same 21 CFR 630.10/630.15 eligibility and testing standards as allogeneic donors. The autologous 11.0 g/dL floor does not apply. MSM-era myths do not create a back door: individual-risk questions still apply. The unit is reserved for the named recipient for a defined window. Practices differ on whether an unused directed unit may later enter general inventory; many hospitals waste a substantial fraction of directed units (AABB 2025 survey data showed high discard rates and inconsistent return-to-inventory policies). Reservation logistics, special handling fees, and outdating are why blood centers discourage non-medically-indicated directed requests.

One directed-specific safety step runs the opposite direction from “safer”: units from blood relatives intended for intrauterine transfusion, neonates, or immunocompromised recipients are irradiated (or pathogen-reduced where that is the center’s equivalent control) to prevent transfusion-associated graft-versus-host disease. A related donor’s lymphocytes may engraft in a haploidentical recipient. Volunteer allogeneic units from unrelated donors are not routinely irradiated solely because they are allogeneic.

Dedicated donors are a close cousin: a person who commits to repeated collections for one patient — HLA-matched or HPA-matched platelets, a neonate expected to need several small-volume transfusions, or a patient with multiple antibodies who has one compatible donor. Dedicated donors still meet full allogeneic criteria. The special handling is inventory reservation and scheduling, not a lighter DHQ.

Therapeutic phlebotomy

Therapeutic phlebotomy removes red-cell mass to treat the donor-patient: hereditary hemochromatosis, polycythemia vera, and porphyria cutanea tarda are the three conditions the BB outline expects by name. Testosterone-associated erythrocytosis is a common modern add-on in center SOPs but is not a substitute for those three on the exam. A physician order is required. Intervals may be shorter than 8 weeks because the procedure is treatment, not volunteer donation (21 CFR 630.15(a)(2)).

Whether the bag can be labeled and issued as allogeneic is a separate question. The container must conspicuously state the disease that necessitated phlebotomy unless all three variance conditions are met: the donor meets all allogeneic eligibility criteria; the condition is hereditary hemochromatosis or another disease FDA has accepted for this purpose and donation will not harm the donor or the product; and the establishment performs therapeutic phlebotomies for that condition without charge. Hemochromatosis units collected under that framework can enter general inventory. Polycythemia vera units often cannot, because the underlying myeloproliferative neoplasm is not treated as an FDA-accepted “label-free allogeneic” condition in the same way. If the variance does not apply, the unit is therapeutic-only (or discarded) and must not be issued as volunteer allogeneic blood.

Do not confuse therapeutic phlebotomy with autologous PAD. The hemochromatosis patient is not donating for an upcoming hip replacement; the patient is being treated for iron overload. The PAD patient is not being treated for iron overload; that patient is banking blood for surgery and is the person most likely to become iron-deficient from the donations.

Emergency uncrossmatched and walking donors

Emergency uncrossmatched red cells are an issue-desk product, not a special collection method. In massive hemorrhage, the transfusion service issues group O red cells (O-negative is preferred for women of childbearing potential; many protocols allow O-positive for adult males and older women once a policy is in place) before a type-and-screen is finished. As soon as the patient’s ABO/Rh is known, the service switches to type-specific uncrossmatched and then to fully crossmatched units. The donor who supplied those O units was a routine allogeneic donor who already passed 21 CFR 630.10. Emergency release does not authorize collecting blood from an unscreened visitor in the hallway.

Walking-donor programs are historical and military: a pre-identified, pre-typed panel of soldiers or shipmates who can be called to a collection point and bled for immediate transfusion to a casualty when stored blood is unavailable. Civilian U.S. hospital practice does not run walking-donor panels as a substitute for an inventory of tested, labeled allogeneic units. If an exam stem romanticizes a “walking donor” as current AABB-standard civilian care, the correct instinct is “historical / austere / military,” not “preferred over volunteer inventory.”

ISBT-128 labeling differences that carry points

ISBT-128 product codes and eye-readable statements tell the issue bench what kind of special unit it is holding:

A DIN is still applied. Special status is not an excuse for a handwritten bag. Autologous and directed requests require a physician order and blood-center physician approval. Informed consent for the donor (and, for directed/autologous, a documented request from the patient’s physician) is part of the record. Plasmapheresis informed consent under 21 CFR 630.15(b)(2) is even more explicit: the responsible physician must explain hemolytic risk if another donor’s cells were ever returned and must re-consent after a 6-month lapse or when the donor enters a new program.

Informed consent and the exam traps, together

Walk into the item with three refusals ready. Do not say directed blood is safer because the donor is known to the family. Do not release an unused autologous unit into allogeneic inventory “because the viral markers were negative.” Do not label a polycythemia vera therapeutic unit as volunteer allogeneic just because the bag is already drawn. Do not treat a walking-donor story as current civilian standard. Do irradiate directed units from blood relatives when the recipient is at TA-GVHD risk. Do keep autologous hemoglobin at 11.0 g/dL / 33% and allogeneic hemoglobin on the 12.5 / 13.0 table. Do remember that emergency uncrossmatched O red cells come from already-qualified allogeneic donors.

Special donations exist to solve a specific clinical problem — a patient’s request, a rare unit, a disease that needs red-cell removal, or a bleeding patient who cannot wait for a crossmatch. They are not a second, looser blood supply.